Eric Roeland News Today

This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention

Jaguar Health Reports Third Quarter 2023 Financial Results

256-patient enrollment target met plus 11% over-enrollment; Primary endpoint based on patient reported outcomes from study expected in October 2023SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2023 / Jaguar

Primary endpoint based on patient reported outcomes from study expected in October 2023With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described

Jaguar Completes Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea Primary endpoint based on patient reported... | May 9, 2023

Jaguar Health subsidiary Napo Pharmaceuticals' OnTarget trial adding international sites, targeting completion of enrollment in Q2 2023SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2022 / Jaguar Health

Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021Core initiatives:OnTarget

Consequences of cancer cachexia can include skeletal muscle loss, fatigue, functional impairment, worse quality of life, and worse survival.

Transaction proceeds will be allocated to support the company's ongoing OnTarget pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults receiving targeted cancer therapySAN

Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials - read this article along with other careers information, tips and advice on BioSpace